Leading Wall Street analysts Josh Brown and Sean Russo, along with Adam Parker, identify a significant rotation of capital from AI stocks into the healthcare sector, driven by strong growth, upward estimate revisions, and low correlation to AI. This strategic shift is benefiting companies in life science and bioprocess tools. Waters (WAT) and Thermo Fisher Scientific (TMO) are highlighted as two names poised to gain, both exhibiting robust financial performance and promising technical indicators amidst this market rebalancing.
A notable shift is underway on Wall Street, as Josh Brown and Sean Russo of Ritholtz Wealth Management, drawing insights from Adam Parker at Trivariate Research, observe a significant reallocation of investor funds. Money, as Brown succinctly puts it, 'doesn't leave the market. It moves.' And currently, the movement is decisively towards healthcare, particularly the burgeoning segment of life science and bioprocess tools, which has already outpaced the broader sector this year.
Adam Parker, who has advocated for healthcare for nearly two years, dismisses concerns of the sector being 'crowded.' He highlights its robust appeal through fast growth, consistent upward estimate revisions, and a crucial low correlation to companies heavily riding the AI revenue wave, thus offering a distinct set of market drivers for investors.
Sean Russo provides tangible evidence of this rotation: a hotter-than-expected CPI print recently saw tech stocks decline 3% in a single day, while healthcare emerged as the S&P 500's top performer, climbing 2.4%. This momentum continued with another 1.8% gain the following day, culminating in the XLV gaining 5.4% over five sessions. While energy (+51%) and tech (+32%) still lead year-to-date through mid-October, healthcare is now a strong third at +12.4%, nearly matching the index's +12.9% after a period of moderate returns. The sector’s forward P/E, relative to the market, was in its lowest quintile of its 15-year range at the start of 2026, suggesting an attractive setup.
Waters Corp. (WAT): Emerging Leader in Lab Instruments
Waters (WAT) is making its debut in this column, recognized for its critical role in life science. The company manufactures sophisticated instruments and consumables essential for separating and identifying molecules, complemented by proprietary software. Its diverse customer base includes pharmaceutical, biotech, academic, food, and environmental entities. A significant expansion occurred in February with its combination with BD's Biosciences & Diagnostic Solutions business, effectively doubling its revenue base.
Despite an initial 9-12% stock decline when the BD deal was announced in July 2025, WAT bottomed at $283 in mid-March 2026, marking a 24.6% year-to-date drop at that point. However, the stock has since staged an impressive comeback, surging 57% to $444, placing it just 2% shy of its record high of $454.54 achieved on October 6.
Waters' Q2 earnings, reported on August 4th, surpassed expectations with revenues of $1.65 billion and adjusted EPS of $3.05. Management subsequently raised its full-year organic constant-currency growth forecast to 7-9% and adjusted EPS guidance to $14.45-$14.65 (a 10-12% increase). For Q3, the company projects revenues between $1.75 billion and $1.762 billion and EPS of $3.95-$4.05. WAT currently trades at approximately 30 times the midpoint of its 2026 EPS guidance and is scheduled to report again on November 3.
WAT Risk Management: Technical Outlook from Josh Brown
Waters powerfully broke out of a spring base in late May, with its August 4th earnings report further propelling the stock, which surged roughly $40 in a single session on double its average volume. Subsequent pullbacks found strong buyer support near $390. A September breakout pushed it to a record high near $455 on October 6, followed by consolidation between $422 and $450. Friday's closing price was $437, with the 50-day moving average rising to $421 and the 200-day at $366. The $455 record high is a crucial level to surpass. With RSI at 56, momentum is balanced after a recent fluctuation. Traders can consider $420 as a stop-loss, aligning with early October lows and the rising 50-day MA. Investors might anchor their risk to $390, a level that successfully held during two prior tests, with a weekly close below it signaling a potential failure of the uptrend.
Thermo Fisher Scientific, Inc. (TMO): A Life Science Powerhouse
Thermo Fisher Scientific (TMO) reigns as the largest entity in the life science tools sector, boasting approximately $46 billion in trailing revenue. Its extensive offerings include analytical instruments, lab consumables, diagnostics, and bioproduction equipment. The company also operates a significant pharma services and clinical research business, a key outsourced component for drug developers, with pharma and biotech contributing around 60% of its revenue.
TMO has delivered exceptional performance since its last mention on November 24, having surged 19% since then. The stock closed recently at a record $696.49, pushing its market capitalization to $257.5 billion. This marks a 60% increase from its 52-week low of $435.27, a 20.5% year-to-date gain, and a 31% rise since mid-July, just before its Q2 earnings report. Several analysts have recently raised their price targets, including JPMorgan and TD Cowen (both at $760), and Guggenheim, which initiated coverage with a 'buy' rating and a $740 target.
The company's Q2 report in July showcased strong results, with revenue of $11.99 billion (+10%, 5% organic) and adjusted EPS of $6.03 (+13%), accompanied by a 0.9-point increase in adjusted operating margin to 22.8%. Management subsequently updated full-year revenue guidance to $47.4 billion-$48.1 billion and adjusted EPS to $24.93-$25.33 (+9%-11%). Furthermore, it projected free cash flow of $6.9 billion-$7.4 billion and a planned $4 billion in share buybacks. TMO has also completed strategic acquisitions (Clario and Solventum filtration) and divested its microbiology business for $1.075 billion in August. At a September conference, management indicated that orders were outpacing revenue, leading to a 4.6% stock surge that day. Trading at about 25.6x forward earnings, TMO is scheduled to report Q3 results before the market open on Wednesday, October 21, with consensus EPS at $6.40 on $11.91 billion in revenue.
TMO Risk Management: Technical Outlook from Josh Brown
Thermo Fisher experienced a significant breakaway gap on July 23, opening near $570 following its Q2 report, and has consistently traded above $555 since. It rallied to $645 by late August, pulled back to $597 in early September, and reached a high near $693 on October 6 before a sharp reversal. After a week of consolidation, it broke out again on Thursday, hitting a new record high near $703. Friday's close was $690, with the 50-day moving average at $637 and the 200-day at $547. Clearing Thursday's high is essential for continued upward momentum. With RSI at 64, momentum is robust and refreshed. Traders can implement a stop-loss at $650, representing the base of the late September/early October range. A close below this level would indicate a failure of the recent breakout. Given the impending Q3 report, the stock could see rapid price movements. Investors can anchor their risk to $600, which marks the early September low and the foundation of the rally since August. A weekly close below $600 would suggest a loss of footing in the current uptrend.
